ASCO23: Glenn Hanna, MD | Dana-Farber Cancer Institute

(1:41)

Izzy Friesner at #ASCO23

(41)

Case Study: Early Identification of Recurrence in Surveillance - Dr. Glenn Hanna

(1:41)

ASCO23 - LBA1: INDIGO: Vorasidenib versus placebo in patients with residual or recurrent grade 2...

(11:11)

Clinical Application of NavDx in the Surveillance Setting (5min) - Dr. Glenn Hanna

(5:13)